Applies to risankizumab: parenteral injection.

Side effects include:

Common adverse effects (≥1%): Upper respiratory infection, headache, fatigue, injection site reaction, tinea infection.

For Healthcare Professionals

Applies to risankizumab: intravenous solution, subcutaneous kit, subcutaneous solution.

Immunologic

Very common (10% or more): Immunogenicity (24%), infections (e.g., cellulitis, osteomyelitis, sepsis, herpes zoster) (22%)

Common (1% to 10%): Tinea infections (e.g., tinea pedis, tinea cruris, body tinea, tinea versicolor, tinea manuum, tinea infection)^[Ref]

Local

Common (1% to 10%): Injection site reactions (e.g., bruising, erythema, extravasation, hematoma, hemorrhage, infection, inflammation, irritation, pain, pruritus, reaction, swelling, warmth)^[Ref]

Respiratory

Very common (10% or more): Upper respiratory infections (e.g., respiratory tract infection [viral, bacterial, unspecified], sinusitis [including acute], rhinitis, nasopharyngitis, pharyngitis [including viral], tonsillitis) (13%)^[Ref]

Other

Common (1% to 10%): Fatigue, asthenia^[Ref]

Nervous system

Common (1% to 10%): Headache (e.g., tension headache, sinus headache, cervicogenic headache)^[Ref]

Dermatologic

Uncommon (0.1% to 1%): Folliculitis, urticaria^[Ref]